Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.

PloS one - 1 Jan 2011

Butler David C, Messer Anne

Abstract excerpt

Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disorder caused by a trinucleotide (CAG)(n) repeat expansion in the coding sequence of the huntingtin gene, and an expanded polyglutamine (>37Q) tract in the protein. This results in misfolding and accumulation of huntingtin protein (htt), formation of neuronal intranuclear and cytoplasmic inclusions, and neuronal dysfunction/degeneration....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Huntingtin Protein
Share to Mice, Transgenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nerve Tissue Proteins

Share to Nuclear Proteins

Share to Ornithine Decarboxylase

Share to Proteasome Endopeptidase Complex

Share to Proteolysis

Source

Open in PubMed Open full text

Identifiers

PMID: 22216210
DOI: 10.1371/journal.pone.0029199
PMCID: PMC3245261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.PMID 22216210Read ↗

Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disordersSemantic proximity Read ↗

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodiesSemantic proximity Read ↗

Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice.Semantic proximity Read ↗

Intrabody applications in neurological disorders: progress and future prospectsSemantic proximity Read ↗

Fully Human Bifunctional Intrabodies Achieve Graded Reduction of Intracellular Tau and Rescue Survival of <i>MAPT</i> Mutation iPSC-derived NeuronsSemantic proximity Read ↗

Human single-chain Fv intrabodies counteract <i>in situ</i> huntingtin aggregation in cellular models of Huntington's diseaseSemantic proximity Read ↗

Development of a novel VHH intrabody targeting the N17 region of huntingtin exon 1 protein that prevents inclusion body formationSemantic proximity Read ↗

Engineered Nanobodies With Programmable Target Antigen Proteolysis (Ptap) Fusions Regulate Intracellular Alpha-synuclein in Vitro and in VivoSemantic proximity Read ↗

Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.Semantic proximity Read ↗

Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative PhenotypesSemantic proximity Read ↗

Targeting tauopathy with engineered tau-degrading intrabodies.Semantic proximity Read ↗

Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.